Manufacturers announce positive one-year data from Phase 3 SPIRIT extension study of once-daily relugolix combination therapy in women with endometriosis

In this study of relugolix (a gonadotropin-releasing hormone antagonist), estradiol and norethindrone combination therapy, 84.8% and 73.3% of women reported clinically meaningful reductions in dysmenorrhea and non-menstrual pelvic pain at one year.

Source:

Biospace Inc.